Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol R&D Success Shows Link Between Licensing And First-Cycle Approval

Executive Summary

Bristol-Myers Squibb's heavy reliance on in-licensing products in the first half of the decade appears to have paid off with a high number of new molecular entity submissions and a relatively strong first-cycle approval record

You may also be interested in...



Bristol Feels Plavix And Pravachol Pain; Does Relief Lie In Conservative R&D?

As Bristol-Myers Squibb prepares to weather patent losses for its two top-selling products - Pravachol and Plavix - the firm is sticking by a conservative approach to research & development

Bristol Feels Plavix And Pravachol Pain; Does Relief Lie In Conservative R&D?

As Bristol-Myers Squibb prepares to weather patent losses for its two top-selling products - Pravachol and Plavix - the firm is sticking by a conservative approach to research & development

Mid-Phase III Meetings Suggested As Way To Increase First-Cycle Approvals

FDA should consider conducting mid-Phase III meetings with drug sponsors as a way to improve the likelihood of approving an application during the first review cycle, a report by Booz Allen Hamilton recommends

Related Content

UsernamePublicRestriction

Register

OM016808

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel